Patient demographics and baseline characteristics
| . | Ph-positive ALL patients . |
|---|---|
| n | 36 |
| Median age, y (range) | 46 (15-85) |
| Male sex, n (%) | 23 (64) |
| Median duration of ALL, mo (range) | 20 (3-97) |
| Any BCR-ABL domain mutation, n (%)* | 25 (78) |
| Imatinib therapy duration, n (%) | |
| Less than 1 y | 16 (44) |
| 1-3 y | 19 (53) |
| More than 3 y | 1 (3) |
| Highest imatinib dose, n (%) | |
| Less than 400 mg | 0 |
| 400-600 mg | 19 (53) |
| More than 600 mg | 17 (47) |
| Prior chemotherapy, n (%) | 32 (89) |
| Prior interferon, n (%) | 3 (8) |
| Prior SCT, n (%) | 15 (42) |
| Median WBC count/mm3 (range); WBC count at least 20 000/mm3, n (%) | 7.0 (0.7-211.0); 11 (31) |
| Leukopenia grade 1-4, n (%) | 11 (31) |
| Median platelets (range); platelets less than 100 000/mm3, n (%) | 53.5 (8.0-360.0); 25 (69) |
| Median peripheral blasts (range); peripheral blasts at least 30%, n (%) | 32 (0.0-100); 11 (31) |
| Median marrow blasts (range) | 69 (0.0-100) |
| . | Ph-positive ALL patients . |
|---|---|
| n | 36 |
| Median age, y (range) | 46 (15-85) |
| Male sex, n (%) | 23 (64) |
| Median duration of ALL, mo (range) | 20 (3-97) |
| Any BCR-ABL domain mutation, n (%)* | 25 (78) |
| Imatinib therapy duration, n (%) | |
| Less than 1 y | 16 (44) |
| 1-3 y | 19 (53) |
| More than 3 y | 1 (3) |
| Highest imatinib dose, n (%) | |
| Less than 400 mg | 0 |
| 400-600 mg | 19 (53) |
| More than 600 mg | 17 (47) |
| Prior chemotherapy, n (%) | 32 (89) |
| Prior interferon, n (%) | 3 (8) |
| Prior SCT, n (%) | 15 (42) |
| Median WBC count/mm3 (range); WBC count at least 20 000/mm3, n (%) | 7.0 (0.7-211.0); 11 (31) |
| Leukopenia grade 1-4, n (%) | 11 (31) |
| Median platelets (range); platelets less than 100 000/mm3, n (%) | 53.5 (8.0-360.0); 25 (69) |
| Median peripheral blasts (range); peripheral blasts at least 30%, n (%) | 32 (0.0-100); 11 (31) |
| Median marrow blasts (range) | 69 (0.0-100) |
Calculated as a proportion of the 32 patients in the Ph-positive ALL cohort who underwent mutational analysis at baseline.